Contribute Try STAT+ Today

Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the waning work hours before the big holiday. Whether you’ve chosen to visit loved ones or observe in isolation, we’d advise you to keep your decision out of the paper of record. In the meantime, here are your requisite tidbits to get the day started. As always, if you hear something interesting out there, do let us know.

The European Union is planning a sweeping change in its rules governing generic drugs, Reuters reports, a move that could cut into the bottom lines of global pharmaceutical firms. The draft law, which could take effect in 2022, would crack down on firms that delay the approval of generics, limit patent protection for companies that don’t make their products available in all 27 member states, and aim to prevent drug shortages across the EU.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.